Candel Therapeutics, Inc. Common Stock

Day range

$7.70 – $8.44

Open

$8.44

Prev close

$8.03

Volume

448.73K

Market cap

$614.44M

Shares out

76.52M

P/E

—

P/S

—

P/B

4.87

P/FCF

—

ROE

-70.2%

ROA

-42.5%

Debt/Equity

0.38

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentSep 10, 2026

  “On September 6, 2026, the Board of Directors ... increased the size of the Board from ten (10) to eleven (11) directors and unanimously appointed Martine Zimmermann, Pharm.D, to fill the newly created vacancy on the Board, effective September 8, 2026.”

• Investor presentationSep 9, 2026

  Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that Candel Therapeutics, Inc. may use from time to time in presentations or discussions with investors, analysts, and other parties.

• Annual meeting resultsJun 24, 2026

  The Company's stockholders elected each of the Class II director nominees, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting.

• Clinical trial resultsMay 15, 2026

  On May 15, 2026, Candel Therapeutics, Inc. (the "Company") held an investor presentation via live webcast to review extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec in localized prostate cancer, which was also presented by the Company during the American Urological Association 2026 Annual Meeting on May 15, 2026.

• Public offeringFeb 23, 2026

  On February 19, 2026, Candel Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Citigroup Global Markets Inc., Cantor Fitzgerald & Co., and Stifel, Nicolaus & Company, Incorporated, as representatives (the "Representatives") of the underwriters named therein (the "Underwriters"), pursuant to which the Company agreed to issue and sell an aggregate of 18,348,624 shares (the "Firm Shares") of its common stock, par value $0.01 per share (the "Common Stock"), at a price to the public of $5.45 per share (the "Offering").

Days to cover

11.2

Short interest

13M

Avg volume

1.17M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Candel Therapeutics to Present at the SITC 2026 Annual Meeting
  positiveGlobeNewswire Inc.· Oct 2, 2026
• 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
  positiveZacks Investment Research· Sep 15, 2026
• Stock Market Today: Dow Jones, S&P 500 Futures Slip After Weaker-Than-Expected GDP Report—Grail, Candel Therapeutics, Copart In Focus (UPDATED)
  negativeBenzinga· Feb 20, 2026
• Candel Therapeutics Announces Pricing of Public Offering
  positiveGlobeNewswire Inc.· Feb 19, 2026
• Candel Therapeutics Announces Proposed $100 Million Public Offering
  neutralBenzinga· Feb 19, 2026